Abstract
Organoselenium compounds have already been reported to be good anticarcinogenic candidates. A new selenoquinazoline derivative, 2,4-bis(selenomethyl)quinazoline (compound 1), has been synthesized, spectroscopically characterized and its crystal structure has been studied. An intermolecular coupling between C2 and \( {\text{H}}_{5}^{\prime } \) in the Heteronuclear Multiple Bond Correlation (HMBC) experiment has been observed. Assuming that the head-to-tail overlap of parallel molecules (as identified by X-ray diffraction) remains in solution to give bimolecular entities, the π–π interaction enables heteronuclear coupling between the former atoms with a three-bond distance [C2···(π–π)···\( {\text{C}}_{5}^{\prime } \)–\( {\text{H}}_{5}^{\prime } \)]. The crystal structure of compound 1 has been solved by X-ray diffraction. It crystallizes in triclinic system, space group P−1. Unit cell parameters are a = 7.4969(7) Å, b = 8.7008(8) Å, c = 10.1666(9) Å, α = 110.215(2)°, β = 90.354(2)°, γ = 115.017(1)°. Linear chains in crystals of compound 1 are generated by C–H···Se and Se···Se bonds between molecules. Furthermore, head-to-tail overlap of parallel molecules, in which π–π interactions can occur, is observed. Compound 1 exhibited a cytotoxic effect in all of the evaluated tumoral cell lines and showed a higher cytotoxic effect in colon and breast cancer cell lines than etoposide, which was used as a reference compound.
Similar content being viewed by others
References
Pan MH, Ho CT (2008) Chemopreventive effects of natural dietary compounds on cancer development. Chem Soc Rev 37:2558–2574
Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Lesher JL Jr, Park HK, Sanders BB Jr, Smith CL, Taylor JR (1996) Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276:1957–1963
Okuno T, Shimamura Y, Mizuno M, Miyata S, Miyake T, Itokawa Y, Takada J, Matsushita R, Koyama M (1988) Trace elements in hepatoma tissue. Trace Elem Med 5:130–136
Boosalis MG (2008) The role of selenium in chronic disease. Nutr Clin Pract 23:152–160
Araldi EMV, Dell’Aica I, Sogno I, Lorusso G, Garbisa S, Albini A (2008) Natural and synthetic agents targeting inflammation and angiogenesis for chemoprevention of prostate cancer. Curr Cancer Drug Target 8:146–155
Zeng H, Combs GF Jr (2007) Selenium as an anticancer nutrient: roles in cell proliferation and tumor cell invasion. J Nutr Biochem 19:1–7
Facompre N, El-Bayoumy K (2009) Potential stages for prostate cancer prevention with selenium: implications for cancer survivors. Cancer Res 69:2699–2703
Peters U, Takata Y (2008) Selenium and the prevention of prostate and colorectal cancer. Mol Nutr Food Res 52:1261–1272
Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301:39–51
El-Bayoumy K (2009) The negative results of the SELECT study do not necessarily discredit the selenium-cancer prevention hypothesis. Nutr Cancer 61:285–286
Ip C (1998) Lessons from basic research in selenium and cancer prevention. J Nutr 128:1845–1854
Ravn-Haren G, Bugel S, Krath BN, Hoac T, Stagsted J, Jorgensen K, Bresson JR, Larsen EH, Dragsted LO (2008) A short-term intervention trial with selenate, selenium-enriched yeast and selenium-enriched milk: effects on oxidative defence regulation. Br J Nutr 99:883–892
Zhao H, Brooks JD (2007) Selenomethionine induced transcriptional programs in human prostate cancer cells. J Urol 177:743–750
Cao TM, Hua FY, Xu CM, Han BS, Dong H, Zuo L, Wang X, Yang Y, Pan HZ, Zhang ZN (2006) Distinct effects of different concentrations of sodium selenite on apoptosis, cell cycle, and gene expression profile in acute promyeloytic leukemia-derived NB4 cells. Ann Hematol 85:434–442
Hu H, Jiang C, Ip C, Rustum YM, Lu J (2005) Methylseleninic acid potentiates apoptosis induced by chemotherapeutic drugs in androgen-independent prostate cancer cells. Clin Cancer Res 11:2379–2388
Sanmartín C, Plano D, Palop JA (2008) Selenium compounds and apoptotic modulation: a new perspective in cancer therapy. Mini Rev Med Chem 8:1020–1031
Wang Z, Hu H, Li G, Lee HJ, Jiang C, Kim SH, Lu J (2008) Methylseleninic acid inhibits microvascular endothelial G1 cell cycle progression and decreases tumor microvessel density. Int J Cancer 122:15–24
Corcoran NM, Najdovska M, Costello AJ (2004) Inorganic selenium retards progression of experimental hormone refractory prostate cancer. J Urol 171:907–910
Plano D, Sanmartín C, Moreno E, Prior C, Calvo A, Palop JA (2007) Novel potent organoselenium compounds as cytotoxic agents in prostate cancer cells. Bioorg Med Chem Lett 17:6853–6859
Ibáñez E, Plano D, Font M, Calvo P, Prior C, Palop JA, Sanmartín C (2011) Synthesis and antiproliferative activity of novel symmetrical alkylthio- and alkylselenocarbamates. Eur J Med Chem 46:265–274
Moreno D, Plano D, Baquedano Y, Jiménez-Ruiz A, Palop JA, Sanmartín C (2011) Antileishmanial activity of imidothiocarbamates and imidoselenocarbamates. Parasitol Res 108:233–239
Sanmartín C, Plano D, Domínguez E, Font M, Calvo A, Prior C, Encío I, Palop JA (2009) Synthesis and pharmacological screening of several aroyl and heteroaroyl selenylacetic acid derivatives as cytotoxic and antiproliferative agents. Molecules 14:3313–3338
Plano D, Baquedano Y, Ibáñez E, Jiménez I, Palop JA, Spallhoz J, Sanmartín C (2010) Antioxidant-prooxidant properties of a new organoselenium compound library. Molecules 15:7292–7312
Plano D, Moreno E, Font M, Encío I, Palop JA, Sanmartín C (2010) Synthesis and in vitro anticancer activities of some selenadiazole derivatives. Arch Pharm Chem Life Sci 10:680–691
Sheldrick GM (1997) SADABS: program for empirical absorption corrections. University of Göttingen, Göttingen, Germany
Sheldrick GM (2008) A short history of SHELX. Acta Crystallogr A 64:112–122
Li Y, Pan J, Li JL, Lee JH, Tunkey C, Saraf K, Garbe JC, Whitley MZ, Jelinsky SA, Stampfer MR, Haney SA (2007) Transcriptional changes associated with breast cancer occur as normal human mammary epithelial cells overcome senescence barriers and become immortalized. Mol Cancer 6:7
Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63
Acknowledgments
The authors wish to express their gratitude to the Ministerio de Educación y Ciencia, Spain (SAF 2009-07744) for financial support. We also thank the Department of Education of the Navarra Government for the award of a grant (E.I.). The authors would like to thank Dr Rafael Sirera, Department of Chemistry and Soil Science, University of Navarra, for helpful discussions of the results of X-ray diffraction. Many thanks to Dr Ángel Álvarez, X-ray diffraction service, Universitat Autònoma de Barcelona, for X-ray experimental assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Plano, D., Ibáñez, E., Palop, J.A. et al. Synthesis, characterization, crystal structure and cytotoxicity of 2,4-bis(selenomethyl)quinazoline. Struct Chem 22, 1233–1240 (2011). https://doi.org/10.1007/s11224-011-9816-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11224-011-9816-x